BRIEF published on 04/01/2025 at 07:05, 8 months 4 days ago Lonza Completes its CHF 2 Billion Share Buyback Program Share Buyback Lonza Financial Strategy Swiss Exchange CHF 2 Billion
PRESS RELEASE published on 04/01/2025 at 07:00, 8 months 4 days ago Lonza Completes its Share Buyback Program Lonza completes its share buyback program, repurchasing 4,239,731 shares on the SIX Swiss Exchange. Board of Directors intends to cancel repurchased shares Board Of Directors Share Buyback Lonza SIX Swiss Exchange Capital Band
BRIEF published on 01/29/2025 at 06:30, 10 months 7 days ago Lonza Reports Stable 2024 Performance with Strategic Shifts Ahead Dividend Announcement Lonza 2024 Performance CDMO Growth One Lonza Strategy Renewable Energy Initiatives
PRESS RELEASE published on 01/29/2025 at 06:25, 10 months 7 days ago Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin Lonza Group AG delivers solid 2024 performance with 29.0% CORE EBITDA margin. Sales at CHF 6.6 billion, in line with prior year. Lonza expects 20% CER sales growth in 2025 Sales Growth Lonza Group AG CORE EBITDA Margin 2024 Performance 2025 Outlook
BRIEF published on 12/12/2024 at 06:30, 11 months 24 days ago Lonza Unveils "One Lonza" Strategy and New Structure Financial Outlook Organizational Change Lonza Strategy CDMO Focus Divestment Plans
PRESS RELEASE published on 12/12/2024 at 06:25, 11 months 24 days ago Lonza Investor Update 2024 Outlines Strategy, New Organizational Structure and Guidance Lonza Investor Update 2024 reveals 'One Lonza' strategy, new organizational structure, and financial guidance highlights for 2025 and beyond CDMO Lonza Organizational Structure Investor Update One Lonza
BRIEF published on 11/12/2024 at 07:05, 1 year ago Lonza Expands Bioconjugation Capabilities in Switzerland Sustainability Lonza ADCs Bioconjugation Visp Expansion
PRESS RELEASE published on 11/12/2024 at 07:00, 1 year ago Lonza to Expand Bioconjugation in Visp (CH) with Two Additional Manufacturing Suites Lonza announces expansion of bioconjugation capabilities in Visp (CH) with two new manufacturing suites, addressing market demand and offering expertise to a broad customer base Expansion Manufacturing Lonza Bioconjugation Visp
BRIEF published on 10/24/2024 at 07:05, 1 year 1 month ago Lonza Group AG Confirms 2024 Outlook Amid Strategic Expansions Manufacturing Expansion Lonza 2024 Outlook Genentech Acquisition CDMO Business Performance Vertex Agreement
PRESS RELEASE published on 10/24/2024 at 07:00, 1 year 1 month ago Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 Lonza confirms Full-Year Outlook 2024 with flat year-on-year sales in CER and high 20s CORE EBITDA margin in Q3 performance update Sales EBITDA Lonza Full-year Outlook Q3 Performance
Published on 12/05/2025 at 02:35, 5 hours 27 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 2 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 57 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 2 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 1 hour 2 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 32 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 12 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 37 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 47 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 14 hours 2 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 17 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 18 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago Declaration of voting rights at the end of November 2025
